Abstracts tagged "Biomarkers"

Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1907 • 2019 ACR/ARP Annual Meeting
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Jacques-Eric Gottenberg¹, Sumanta Mukherjee ², Marleen Nys ³, Robert Wong ⁴, Hendrika Bootsma ⁵ and Neelanjana Ray ⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁴Bristol-Myers Squibb, Princeton, ⁵University of Groningen, Groningen, Netherlands
Background/Purpose: Chemokine (C-X-C motif) ligand 13 (CXCL13), produced by follicular helper T (Tfh) cells, plays a pivotal role in B-cell homing and activation in germinal…
Abstract Number: 1020 • 2019 ACR/ARP Annual Meeting
NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus
Ming-Han Chen¹, Yen-Po Tsao ¹ and Szu-Ting Chen ², ¹Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Institutes of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (Republic of China)
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease with diverse etiological factors. It was well recognized that interferon (IFN) signature did the perpetration…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 724 • 2018 ACR/ARHP Annual Meeting
Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?
Kelly Liang¹, Kimberly P. Liang², Yaming Li³, Alex Hurd³, Douglas Landsittel⁴ and Sheldon Bastacky⁵, ¹Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Biostatistics, University of Pittsburgh, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Traditional biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN) include serum creatinine (Cr), complement levels (C3/C4), double-stranded DNA antibody (dsDNA), erythrocyte sedimentation…
Abstract Number: 1084 • 2018 ACR/ARHP Annual Meeting
Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis
Johannes Hartl¹, Robert M. Clancy¹, Peter M. Izmirly², H. Michael Belmont¹, Nicole Kaiden³, Nicole Bornkamp³, Vanja Sisirak¹, Benjamin Sally¹, Jill P. Buyon¹ and Boris Reizis¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY
Background/Purpose: DNASE1L3 is a unique secreted DNase that is capable of degrading DNA complexed with proteins and/or encapsulated in membranes, such as chromatin within microparticles…
Abstract Number: 1484 • 2018 ACR/ARHP Annual Meeting
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
Maresa Grundhuber¹, Daniela Sieghart², Günter Steiner², Maryam Poorafshar³ and Sascha Swiniarski¹, ¹Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ³Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP)…
Abstract Number: 2020 • 2018 ACR/ARHP Annual Meeting
Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis
Lauren M. Pachman^1,2, Shefa Tawalbeh³, Gabrielle A. Morgan⁴, Wilfredo Marin⁴, Laurie Conklin⁵, Yetrib Hathout⁶ and Eric Hoffman³, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Binghampton University, Binghampton, NY, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Children’s National Medical Center, Washington, DC, ⁶Pharmaceutical Sciences, Binghampton University, Binghampton, NY
Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis Background/Purpose: Juvenile Dermatomyositis (JDM) is a complex autoimmune…
Abstract Number: 2899 • 2018 ACR/ARHP Annual Meeting
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Xavier M Teitsma¹, Johannes W. G. Jacobs², Arno N Concepcion³, Attila Pethö-Schramm⁴, Michelle EA Borm⁵, Jacob van Laar¹, Johannes W. J. Bijlsma⁶ and Floris PJG Lafeber¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Roche Nederland BV, Woerden, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The…
Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Yair Molad^1,2, Mohammad Egbaria³, Ariela Dortort-Lazar^4,5, Elisheva Pokroy-Shapira^3,5, Shirly Oren⁴, Yonatan Edel^3,5 and Vitaly Kliminski^5,6, ¹Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, ²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁴Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
Abstract Number: 1089 • 2018 ACR/ARHP Annual Meeting
Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms
Robert M. Clancy¹, Carl Langefeld², Hannah C. Ainsworth³, H. Michael Belmont¹, Martin Blaser⁴, Peter M. Izmirly⁵, Corey Lacher¹, Miranda C Marion⁶, Mala Masson¹, Gregg Silverman⁷ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Director of the NYU Human Microbiome Program, NYU School of Medicine, New York, NY, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-Ro60 autoantibodies are present in asymptomatic individuals years before onset of disease. We hypothesize that differences in autoreactivity-inducing commensal abundances may drive progression to…
Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Carol Hitchon¹, Victor Spicer¹, Nathalie Carrier², Ang Gao¹, Hani El-Gabalawy¹, John Wilkins¹ and Gilles Boire³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…
Abstract Number: 2023 • 2018 ACR/ARHP Annual Meeting
Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases
Adriana Almeida de Jesus¹, Yanfeng Hou², Louise Malle³, Scott Canna⁴, Gina A. Montealegre Sanchez¹, Hanna Kim⁵, Rachel VanTries¹, Seza Ozen⁶, Samantha Dill⁷, Dawn C. Chapelle⁷, Bernadette Marrero¹, Yan Huang¹, Angelique Biancotto⁸ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Department of Rheumatology, Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴RK Mellon Institute for Pediatric Research, University of Pittsburgh/Children's Hospital of Pittsburgh of UPMC, Pittsburrgh, PA, ⁵Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁶Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁷Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ⁸Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD
Background/Purpose: Many infants and children with early-onset autoinflammatory diseases are mutation-negative for genetically known autoinflammatory diseases. Recent data suggest a role for Type-I interferon dysregulation…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 740 • 2018 ACR/ARHP Annual Meeting
Can Monocyte Chemo-Attractant Protein-1differentiate Different Histological Classes in Lupus Nephritis?
Varun Dhir¹, Ranjeeth Kumar Gone², Amit Sandhu³, Aman Sharma⁴, Shefali Sharma⁵, Ritambhra Nada², Sanjay Jain⁶ and Manish Rathi⁷, ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁵Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁶Postgraduate Institute of Medical Education and Research, Chandigarh, India, CHANDIGARH, India, ⁷Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Lupus Nephritis one of the commonest manifestations of SLE. Despite being the gold standard in Lupus nephritis, renal biopsy is an invasive procedure with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].